/
Park Ha Biological Technology Co., Ltd. is a consumer products company focused on skincare and cosmetic products under its proprietary Park Ha brand. The company develops and manufactures skincare solutions aimed primarily at addressing problematic skin, including offerings for basic skin protection, exfoliation, sebum film repair, microecological balance at the skin surface, and anti-aging care. Its business is organized around two main segments: Product Sales and Franchise Service, reflecting a model that combines direct product distribution with franchise-based promotion and retail operations. Park Ha Biological Technology Co., Ltd. markets its products through directly operated stores as well as a network of franchisees across China, where its operating subsidiaries also provide in-store beauty services and after-sales skincare support. Founded in 2016 and headquartered in Wuxi, China, the company today occupies a niche within the household and personal care industry, focusing on specialized skincare solutions delivered via a mix of proprietary retail locations and franchise partners.
$0.46
+$0.03 (+7.55%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-956.45% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 6.0%, steady but not accelerating. Margins contracted 989.8pp, which offsets some of the top-line progress.
Free cash flow declined 100% versus the prior year, cash generation momentum has weakened. ROIC dropped from 36.54% to -663.41%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3M
▲ +6.0% YoY
Net Income (TTM)
-$24M
▼ -5191.3% YoY
Op. Margin
-956.45%
▼ -989.8pp YoY
ROIC
-663.41%
▼ -699.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3K
▼ -100.3% YoY
Op. Cash Flow (TTM)
$86K
▼ -91.1% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
3Y CAGR: +9.6%
Continue Research
Park Ha Biological Technology Co. (BYAH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Park Ha Biological Technology Co. scores 31/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Park Ha Biological Technology Co. scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -956.5% operating margin and a -663.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BYAH's valuation and scores 31/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.